Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunovant Inc (NQ: IMVT )

28.07 +0.11 (+0.38%)
Streaming Delayed Price Updated: 2:33 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 379,920
Open 28.19
Bid (Size) 28.06 (3)
Ask (Size) 28.09 (3)
Prev. Close 27.97
Today's Range 27.78 - 28.81
52wk Range 18.82 - 45.58
Shares Outstanding 114,998,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
Via Investor's Business Daily
IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024
IMVT stock results show that Immunovant missed analyst estimates for earnings per share the fourth quarter of 2024. 
Via InvestorPlace

Performance

YTD
-32.17%
-32.17%
1 Month
+2.76%
+2.76%
3 Month
-2.31%
-2.31%
6 Month
-29.88%
-29.88%
1 Year
+28.37%
+28.37%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
Via Benzinga
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Recap: Immunovant Q3 Earnings
Via Benzinga
Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Via Investor's Business Daily
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Via InvestorPlace
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Via Investor's Business Daily
Argenx Dives On Autoimmune Therapy Failure
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Via InvestorPlace
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
Via InvestorPlace
3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024
Via InvestorPlace
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
Via The Motley Fool
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Via Investor's Business Daily
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
Via Investor's Business Daily
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Via Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.